NDA 203595 · Braintree Labs
Suclear
Magnesium Sulfate, Polyethylene Glycol 3350, Potassium Chloride, Potassium Sulfate, Sodium Bicarbonate, Sodium Chloride, Sodium Sulfate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 15, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jan 18, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SUCLEAR · MAGNESIUM SULFATE 1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A; POLYETHYLENE GLYCOL 3350 N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Suclear" as an intervention, any sponsor and status, largest first.
- Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly PeoplePivotal-lookingStatus unknown
KangWon National University HospitalAcademic, hospital or other
NCT03520361 · 198 participants (planned) · Start Nov 2, 2017 · Primary completion Apr 30, 2019
Drug: Oral sulfate solution (OSS); 2L PEG/Asc · For: Colonoscopy
Sites: Chuncheon, South Korea
- Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel PreparationPivotal-lookingCompleted
National Cancer Center, KoreaGovernment (non-federal)
NCT02551198 · 184 participants · Start Nov 1, 2015 · Primary completion Mar 1, 2016
Drug: HAPREP®; SUCLEAR® · For: Healthy
Sites: Goyang-si, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Braintree Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.